Epithelioid sarcoma: the University of Washington experience
Epithelioid sarcoma: the University of Washington experience
复制标题
DOI：
10.1016/j.amjsurg.2007.07.029
复制
发表时间：
2008-09-01
影响因子：
3
通讯作者：
Mann, Gary N.
中科院分区：
文献类型：
--
作者：
Wolf, Patrick S.;Flum, David R.;Mann, Gary N.
背景：上皮样肉瘤是一种罕见的肉瘤，局部复发率高，经常转移到淋巴结。我们回顾了我们对这种疾病患者进行辅助治疗的经验。方法：1990年至2003年，我们治疗了11例上皮样肉瘤。分析患者、肿瘤和治疗特征，并通过Kaplan-Meier方法评价治疗对生存率的影响。结果：9名男性和2名女性接受了治疗。肿瘤出现在躯干、上肢和下肢。5例患者发生淋巴结疾病。所有患者均接受了原发肿瘤手术，7例患者进行了淋巴结评估。10例患者接受了辅助化疗，9例接受了放疗。9例复发。5年无病生存率和总生存率分别为46%和65%。化疗和放疗不影响无病生存率。结论：虽然手术仍然是主要的治疗方式，但需要多机构试验来开发更有效的上皮样肉瘤患者的辅助治疗。(c)2008年爱思唯尔公司All rights reserved.
BACKGROUND: Epithelioid sarcoma is a rare sarcoma with a high local recurrence rate that frequently metastasizes to lymph nodes. We reviewed our experience with adjuvant therapy in patients with this disease. METHODS: Between 1990 and 2003, we treated 11 patients with epithelioid sarcoma. Patient, tumor, and treatment characteristics were analyzed, and effect of treatment on survival was evaluated by the Kaplan-Meier method. RESULTS: Nine men and 2 women were treated. Tumors presented on the trunk, the upper extremities, and the lower extremities. Five patients developed nodal disease. All patients underwent surgery for the primary tumor, and 7 patients had nodal evaluation. Ten patients underwent adjuvant chemotherapy, and 9 underwent radiotherapy. Recurrence developed in 9 patients. Five-year disease-free and overall survival rates were 46% and 65%, respectively. Chemotherapy and radiation therapy did not impact disease-free survival. CONCLUSIONS: Although surgery remains the primary treatment modality, multi-institutional trials are needed to develop more effective adjuvant therapy for patients with epithelioid sarcoma. (c) 2008 Elsevier Inc. All rights reserved.